ArticleInvestigational new drugs2014

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.

Roberto Pili et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.